Valeant gets right to develop AstraZeneca's psoriasis drug
September 01, 2015 at 02:28 AM EDT
Sept 1 (Reuters) - Canada's Valeant Pharmaceuticals International Inc said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.